NUT Midline Carcinoma
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors (NCT02307240) | Curis, Inc. | 2014-11-01 |
| A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) (NCT02259114) | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2014-10-23 |
Track NUT Midline Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.